Journal abstracts

March 1999
Palliative Medicine;1999, Vol. 13 Issue 2, p173
Academic Journal
Presents an abstract of the paper `The Problem of Weakness in Patients with Advanced Cancer,' by D.J.F. Brown, published in the `International Journal of Palliative Nursing.' Focus on the symptom of weakness as a physical aspect of the weakness-fatigue complex in cancer.


Related Articles

  • Cancer-Induced Cachexia: A Guide for the Oncologist. Gullett, Norleena; Rossi, Peter; Kucuk, Omer; Johnstone, Peter A. S. // Journal of the Society for Integrative Oncology;Fall2009, Vol. 7 Issue 4, p155 

    Cancer-induced cachexia (CIC) is a paraneoplastic syndrome that may account for up to 20% of deaths in cancer patients. Cachexia includes distinct metabolic changes that are the result of an acute-phase response (APR) mounted by the host as a reaction to tumor cells. These changes include...

  • Nutritional Support in Cancer. Costelli, Paola; Muscaritoli, Maurizio; Penna, Fabio; Bonetto, Andrea; Minero, Valerio Giacomo; Aversa, Zaira; Iannuzzi, Silvia; Bonelli, Gabriella; Baccino, Francesco M.; Fanelli, Filippo Rossi // Current Nutrition & Food Science;2007, Vol. 3 Issue 3, p242 

    The management of cancer patients is frequently complicated by the occurrence of cachexia, a complex syndrome characterized by marked depletion of body weight, associated with profound alterations of both nutritional status and metabolic homeostasis. Progressive wasting of skeletal muscle mass...

  • Understanding cachexia in patients with cancer. Holmes, Susan // Nursing Standard;1/26/2011, Vol. 25 Issue 21, p47 

    Cancer cachexia is a progressive wasting syndrome characterised by loss of both adipose tissue and lean body mass. It is a complex metabolic process common in patients with cancer and responsible for death. Consideration of this syndrome is important because of its prevalence and its significant...

  • Fatigue experience in advanced cancer: a phenomenological approach. Potter, Joan // International Journal of Palliative Nursing;Jan2004, Vol. 10 Issue 1, p15 

    This study describes the experience of fatigue in patients with advanced cancer. A phenomenological approach was adopted to allow a fuller expression of the phenomenon of fatigue in the sample of six patients. Five major themes were identified. These were physical, psychological, social and...

  • Sunitinib.  // Reactions Weekly;9/28/2013, Issue 1471, p39 

    The article presents a case study of a man who developed asthenia and neutropenia while being treated with sunitinib for recurrent thyroid cancer.

  • Rehabilitation for elderly patients with cancer asthenia: making a transition to palliative care. Scialla, S.; Cole, R.; Scialla, T.; Bednarz, L.; Scheerer, J. // Palliative Medicine;Mar2000, Vol. 14 Issue 2, p121 

    The transition from curative to palliative care for elderly patients with cancer-related asthenia presents complex challenges to oncologists. A result of this complexity is a lack of regard for the maintenance of physical and mental function. This study examined the effects of comprehensive,...

  • Fatigue et cancer.  // Oncologie;Jul2011, Vol. 13 Issue 7, p346 

    No abstract available.

  • Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study. Ardizzoia, A.; Acquati, M.; Fagnani, D.; Giordano, M.; Visini, M.; Scanni, A.; Quattrone, A.; Fusco, O.; Vergani, C.; Casartelli, C.; Tagliabue, P.; Malugani, F. // Lung;2004, Vol. 182 Issue 1, p1 

    Docetaxel is one of the most active drugs in second-line therapy for non-small-cell-lung-carcinoma (NSCLC). The aim of this multicenter study was to evaluate the safety and efficacy of weekly low-dose docetaxel. Forty-two patients with advanced NSCLC pretreated with cisplatinum-based...

  • Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Procopio, G.; Verzoni, E.; Bracarda, S.; Ricci, S.; Sacco, C.; Ridolfi, L.; Porta, C.; Miceli, R.; Zilembo, N.; Bajetta, E. // British Journal of Cancer;4/12/2011, Vol. 104 Issue 8, p1256 

    Background: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma (mRCC).Methods: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400 mg twice...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics